According to a national health survey by the Australian Bureau of Statistics, it was found that in the year 2017-2018, almost half of the population of Australia (47.3%) had one or more chronic conditions, which shows an increase from the previous data of (42.2.%) for the year 2007-2008. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. have a chronic disease, and 4 in 10 adults have two or more chronic disease
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-lyophilized-injectable-drugs-market
Global Lyophilized Injectable Drugs Market is expected to reach USD 6,791.25 million by 2028 from USD 4,318.00 million in 2020, growing with a substantial CAGR of 6.2% in the forecast period of 2021 to 2028. Chronic diseases are caused due to various risk behaviors such as poor nutrition, excessive alcohol consumption, tobacco use, and lack of physical activity. The increased incidence of chronic diseases raises the demand for the prognosis of such diseases via proper advanced medications, thereby propelling the growth of the global lyophilized injectable drugs market. Many market players are involved in offering the lyophilized injectable drugs products with innovations that pave the way for the growth of the lyophilized injectable drugs market.
The overall rise in the chronic health conditions across the world will drive the market's growth rate
Chronic diseases are caused due to various risk behaviors such as poor nutrition, excessive alcohol consumption, tobacco use, and lack of physical activity. The increased incidence of chronic diseases raises the demand for the prognosis of such diseases via proper advanced medications, thereby propelling the growth of the global lyophilized injectable drugs market. The rising incidence of chronic diseases, including diabetes, cardiovascular diseases, and cancer, is expected to accelerate the demand for lyophilized injectable drugs, among others, to cure these conditions. Thus, the increased incidence rates of chronic diseases are boosting the growth of the market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2013 - 2018)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Packaging (Vials, Dual-Chamber Syringes, Dual-Chamber Cartridges and Others), Drug Class (Anti-Infective, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, Corticosteroids and Others), Form (Powder and Liquid), Indication (Oncology, Autoimmune Diseases, Hormonal Disorders, Respiratory Diseases, Gastrointestinal Disorders, Dermatological Disorders, Ophthalmic Diseases and Others), Route of Administration (Intravenous/Infusion, Intramuscular and Others), End User (Hospital, Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Affy Pharma Pvt Ltd. (India), Genex Pharma (India), AuroMedics Pharma LLC (U.S.), Astellas Pharma Inc. (U.S.), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Cirondrugs (India), Amneal Pharmaceuticals LLC (U.S.), Jubilant Generics Limited (India), Novartis AG (Switzerland), Otsuka America Pharmaceutical, Inc. (U.S.), Zydus Cadila (India), Cipla Inc. (India), Merck Sharp & Dohme Corp. (Germany), Fresenius Kabi (U.S.), Sanofi (France), Celon Laboratories Pvt. Ltd. (India) and Baxter (U.S.) among others.
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global lyophilized injectable drugs market is categorized into seven notable segments which are based on the packaging, drug class, form, indication, route of administration, end user and distribution channel.
- On the basis of packaging, global lyophilized injectable drugs market is segmented into vials, dual-chamber syringes, dual-chamber cartridges and others. In 2021, vials segment is expected to dominate the lyophilized injectable drugs market with 74.48% market share because most of the lyophilized injectable drugs are packaged in vials, so it is influential as well as growing in the market.
- On the basis of drug class, global lyophilized injectable drugs market is segmented into anti-infectives, antineoplastic, diuretics, proton pump inhibitor, anesthetic, anticoagulant, NSAID’s, corticosteroids and others. In 2021, anti-infectives segment is expected to dominate the lyophilized injectable drugs market with 44.30% market share because of the increased demand for the antibiotics and antiviral drugs across globe.
- On the basis of form, global lyophilized injectable drugs market is segmented into powder and liquid. In 2021, powder segment is expected to dominate the lyophilized injectable drugs market with 93.60% market share because of its easy and safe storage plus transportation across globe.
- On the basis of indication, global lyophilized injectable drugs market is segmented into oncology, autoimmune diseases, hormonal disorders, respiratory diseases, gastrointestinal disorders, dermatological disorders, ophthalmic diseases and others. In 2021, oncology segment is expected to dominate the lyophilized injectable drugs with 48.36% market share because of the availability of increased number of lyophilized injectable drugs for oncology.
- On the basis of route of administration, global lyophilized injectable drugs market is segmented into intravenous/infusion, intramuscular and others. In 2021, intravenous/infusion segment is expected to dominate the lyophilized injectable drugs market with 73.04% market share because of the 100% bioavailability of the drug via this route of administration.
- On the basis of end user, global lyophilized injectable drugs market is segmented into hospital, clinics, home healthcare and others. In 2021, hospital segment is expected to dominate the lyophilized injectable drugs market with 37.83% market share due to the financial capabilities of hospitals to purchase luxurious equipment along with the presence of trained professionals to administer them.
The hospital segment will dominate the end user segment of the lyophilized injectable drugs market
The hospital segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
- On the basis of distribution channel, global lyophilized injectable drugs market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the lyophilized injectable drugs market with 82.99% market share because most of the service providers buy the lyophilized injectable drugs from manufacturers and it is noticed that revenue from direct sales is higher, so it is influential as well as growing in the market.
The direct tender segment will dominate the distribution channel segment of the lyophilized injectable drugs market
The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the chemicals and materials industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in surface disinfectants market: Affy Pharma Pvt Ltd. (India), Genex Pharma (India), AuroMedics Pharma LLC (U.S.), Astellas Pharma Inc. (U.S.), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Cirondrugs (India), Amneal Pharmaceuticals LLC (U.S.), Jubilant Generics Limited (India), Novartis AG (Switzerland), Otsuka America Pharmaceutical, Inc. (U.S.), Zydus Cadila (India), Cipla Inc. (India), Merck Sharp & Dohme Corp. (Germany), Fresenius Kabi (U.S.), Sanofi (France), Celon Laboratories Pvt. Ltd. (India) and Baxter (U.S.).
Market Development
- In November 2019, Novartis AG announced that it has undergone a strategic agreement with the Medicines Company, the U.S. based pharmaceutical company. This agreement done by the company has strengthened its innovative medicine product portfolio leading to increased sales and revenue in the market
- In August 2020, Jubilant Pharma Limited announced that it had launched its product named JUBI-R, which is Remdesivir for injection for COVID-19. This product launched by the company during the tough times of COVID-19 pandemic, has increased its credibility and demand in the market
- In July 2020, Fondaco Pte Ltd announced that it had recalled its product named euronox Lyophilized Powder for Injection 100 units/vial at retail-level due to potential quality issues. This product recall done by the company has decreased its credibility in the market-leading to decreased demand for its product in the market
- In January 2019, Sun Pharmaceutical Industries Inc. announced that its wholly-owned subsidiary Sun Pharmaceutical Industries, Ltd announced the voluntary recall of three lots of Vecuronium Bromide for Injection 10 mg, 20 mg (lyophilized powder) and injection to the hospital level due to the presence of glass in them. This product recall done by the company has decreased its credibility in the market-leading to decreased demand for its product in the market
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in lyophilized injectable drugs market during the forecast period 2021 to 2028
- In 2021, North America is dominating in the lyophilized injectable drugs market due to the presence of major market players and increased technological advancement in the region.
Asia-Pacific is estimated to be the fastest growing region in lyophilized injectable drugs market the forecast period 2021 to 2028
During the projected forecast period, Asia-Pacific is anticipated to be the fastest developing region due to the increasing demand of lyophilized drugs for various diseases and increased R&D laboratories for drug testing.
COVID-19 Impact
Studies are currently being conducted to determine the effectiveness and safety of new therapeutic drugs that have been lyophilized in the treatment of hospitalized adult COVID-19 patients. In the midst of all of this, pharmaceutical giant Cipla, a major player in the healthcare industry, is receiving praise for the introduction of its CIPREMI Remdesivir lyophilized powder for injection (100mg). In order to boost the accessibility of the U.S. FDA-approved emergency use authorization (EUA) medication for patients with severe COVID-19 symptoms, manufacturers in the lyophilized injectable market are taking ideas from such advances.
For more detailed information about the lyophilized injectable drugs market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-lyophilized-injectable-drugs-market
